New drug cocktail aims to shrink Hard-to-Treat kidney tumors
NCT ID NCT04981509
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing whether a combination of three drugs—bevacizumab, erlotinib, and atezolizumab—can safely shrink or stabilize advanced kidney cancer in people with hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer. The drugs work by cutting off tumor blood supply, blocking cancer growth signals, and boosting the immune system. The study will enroll 65 participants and measure safety, tumor response, and survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
bevacizumab, erlotinib, and atezolizumab
What this could lead to
If this combination works, it could offer a new treatment option for people with advanced hereditary or sporadic papillary kidney cancer, potentially shrinking tumors or slowing disease progression.
What could go wrong
This is a small, early-phase trial (65 people) focused on safety and initial effectiveness. The combination may cause significant side effects, and results may not apply to all patients or lead to a standard treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Emory Saint Joseph's Hospital
RECRUITINGAtlanta, Georgia, 30342, United States
Contact
Contact Phone: •••-•••-••••
-
Emory University Hospital Midtown
RECRUITINGAtlanta, Georgia, 30308, United States
Contact
Contact Phone: •••-•••-••••
-
Emory University Hospital/Winship Cancer Institute
RECRUITINGAtlanta, Georgia, 30322, United States
Contact
Contact Phone: •••-•••-••••
-
Laura and Isaac Perlmutter Cancer Center at NYU Langone
ACTIVE_NOT_RECRUITINGNew York, New York, 10016, United States
-
NCI - Center for Cancer Research
RECRUITINGBethesda, Maryland, 20892, United States
Contact
Contact Phone: •••-•••-••••
-
NYU Langone Hospital - Long Island
ACTIVE_NOT_RECRUITINGMineola, New York, 11501, United States
-
National Institutes of Health Clinical Center
SUSPENDEDBethesda, Maryland, 20892, United States
-
Northwestern University
RECRUITINGChicago, Illinois, 60611, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Ohio State University Comprehensive Cancer Center
RECRUITINGColumbus, Ohio, 43210, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Rutgers Cancer Institute of New Jersey
RECRUITINGNew Brunswick, New Jersey, 08903, United States
Contact
Contact Phone: •••-•••-••••
-
UC San Diego Moores Cancer Center
RECRUITINGLa Jolla, California, 92093, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UT MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Pittsburgh Cancer Institute (UPCI)
RECRUITINGPittsburgh, Pennsylvania, 15232, United States
Contact
Contact Phone: •••-•••-••••